--- title: "ImmuCell Earnings Call Highlights Record Growth Push" type: "News" locale: "en" url: "https://longbridge.com/en/news/286627711.md" description: "ImmuCell (ICCC) reported a record Q1 FY2026 with product sales exceeding $10 million for the first time, up 28.4% year-over-year. Net income rose 34% to $1.9 million. The U.S. market drove growth, while international sales declined. Gross margin improved to 45%, despite cost challenges. The company is expanding its commercial footprint and investing in capacity to meet future demand, although manufacturing risks remain. Overall, the earnings call highlighted strong performance and optimistic growth prospects." datetime: "2026-05-16T00:17:38.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286627711.md) - [en](https://longbridge.com/en/news/286627711.md) - [zh-HK](https://longbridge.com/zh-HK/news/286627711.md) --- # ImmuCell Earnings Call Highlights Record Growth Push Immucell ((ICCC)) has held its Q1 earnings call. Read on for the main highlights of the call. ### Claim 55% Off TipRanks - Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions - Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks ImmuCell’s latest earnings call struck an upbeat tone, as management celebrated a record revenue quarter, stronger profitability, and visible market share gains in its core U.S. business. While executives acknowledged lingering risks around manufacturing capacity, contamination controls, and softer international sales, they argued that operational progress and cash for expansion position the company well for 2026 demand. ## Record Revenue Milestone and Profit Upswing ImmuCell delivered its first-ever $10 million-plus quarter, with Q1 FY2026 product sales reaching $10.4 million, up 28.4% year over year. Net income climbed 34% to $1.9 million, or $0.21 per share, while adjusted EBITDA rose to $2.6 million, underscoring that growth is translating into stronger earnings and cash generation. ## Domestic Market Powers Growth While Overseas Lags The company’s U.S. business did the heavy lifting, with domestic sales surging 35.7% to $9.7 million and driving nearly all of the quarter’s revenue expansion. In contrast, international product sales slid 30.2% to roughly $0.6 million, highlighting a weak global contribution even as management invests in groundwork for disciplined expansion abroad. ## Margin Expansion Despite Cost Headwinds Gross margin improved to 45.0% of product sales in Q1 FY2026, up from 41.6% a year earlier, even after absorbing a 2.4 percentage point drag from legacy cost reclassification. The better margin profile reflects both scale benefits and operational efficiencies, giving the company more room to absorb rising operating expenses tied to growth investments. ## Tri-Shield Momentum Anchors Premium Strategy Tri-Shield, the company’s flagship product, continued to outpace the broader portfolio with sales up 38.5% year over year, making a meaningful contribution to overall revenue. Management framed this as validation of Tri-Shield’s premium positioning in the calf scours prevention market and a key driver of ImmuCell’s competitive edge. ## Manufacturing Output and Yield Step-Change Manufacturing output exceeded 450,000 units per month during Q1 FY2026, up from 380,000 per month in 2025 and significantly above historical levels. This step-change was credited to better planning, reduced waste, selective capital spending, and more disciplined overtime, all of which are crucial to keeping up with accelerating demand. ## Market Share Gains in a Moderating Category ImmuCell’s share of U.S. category dollar spend has risen from 29.1% in 2021 to 35.2% in Q1 2026, while its share of animals treated increased from 15% to 18.1%. Management estimates the company captured nearly 80% of the quarter’s total category dollar expansion, even as overall scours biologics category growth slowed to about 11% from roughly 14% last year. ## Strengthened Balance Sheet and Capacity War Chest The balance sheet improved, with cash at $6.8 million, inventory at $8.7 million, and working capital growing from $13.0 million at year-end 2025 to $15.0 million by March 31, 2026. A $2.0 million settlement provides incremental capital earmarked for capacity expansion, giving ImmuCell added financial flexibility to invest ahead of expected demand. ## Commercial Expansion and Talent for the Next Leg To support its growth ambitions, ImmuCell expanded its U.S. commercial footprint by adding a third Western sales territory and increasing sales headcount to deepen direct customer engagement. The company also recruited an international business development leader, signaling an intent to build a more systematic and measured approach to global market entry over time. ## Cost Inflation and Lost One-Off Income Operating expenses climbed to $2.7 million from $2.2 million a year earlier, driven mainly by higher general and administrative spending and expanded sales costs tied to leadership additions and commercial acceleration. Other income swung from a $330,000 benefit last year, helped by a one-time insurance payment, to a modest $15,000 expense, removing a small nonrecurring boost from the comparison. ## Manufacturing Constraints and Supply Variability Risks Management underscored that manufacturing remains a key execution risk, with contamination threats and the need for major capacity upgrades at the colostrum processing plant still front and center. Past backorders and availability issues have distorted product mix and timing between Tri-Shield and other SKUs, and ongoing supply-side variability could lead to uneven revenue in the near term. ## Forward-Looking Expansion Focused on Capacity and Availability Looking ahead, the company’s guidance centers on keeping First Defense products available while executing a significant capacity expansion funded in part by the $2.0 million settlement. Priorities include deploying advanced drying equipment, pushing further yield gains beyond the current 450,000-plus units per month, managing contamination risk, and finalizing processing-plant upgrades to stay ahead of demand through the rest of 2026. ImmuCell’s record quarter, margin gains, and expanding U.S. market share provided a clear bullish backdrop to the earnings call, even as management acknowledged higher costs, international softness, and manufacturing risks. For investors, the story now hinges on whether the company can successfully execute its capacity build-out and sustain product availability while capitalizing on a still underpenetrated calf health market. ### Related Stocks - [ICCC.US](https://longbridge.com/en/quote/ICCC.US.md) ## Related News & Research - [10:02 ETPurina Pro Plan Veterinary Supplements Launches FortiFlora Diarrhea Response Kit](https://longbridge.com/en/news/295418627.md) - [Wharf Holdings declares interim dividend of HKD 0.2 a share](https://longbridge.com/en/news/295483551.md) - [How Investors Are Reacting To IES Holdings (IESC) Surging Q3 2026 Sales And Nearly Doubled Profit](https://longbridge.com/en/news/295332117.md) - [3 Low Risk Stocks For Defensive Portfolios As Bond Yields Swing](https://longbridge.com/en/news/295332287.md) - [HUYA Q2 FY26 net income turns to RMB 1.6 million; net revenue rises 11% to RMB 1.74 billion](https://longbridge.com/en/news/295505373.md)